HILLSIDE, N.J., Aug. 14, 2007 (PRIME NEWSWIRE) -- Integrated BioPharma, Inc. (Nasdaq:INBP) announced that its subsidiary, InB:Biotechnologies, Inc. (InB:Bio) has developed what it believes is a novel, proprietary platform technology for the rapid, efficient and economical manufacture of biopharmaceuticals, including vaccine antigens, antibodies and other therapeutic proteins. The Company believes that implementation of this technology could conceptually change and revolutionize biomanufacturing. The Company intends to realize value from this proprietary intellectual property by licensing its use to others, in each case for a specific application, and to derive revenues, largely net, from royalties and other payments related to the use of the intellectual property for the production of a subject biopharmaceutical product.
